Evaluating the Effect of One-Week GLP-1 Receptor Agonist Discontinuation Before Esophagogastroduodenoscopy on Gastric Preparation Quality

What this Trial Is About

Researchers are studying whether stopping long-acting glucagon-like peptide-1 receptor agonists GLP-1 RAs for one week before an esophagogastroduodenoscopy EGD improves the quality of stomach preparation and reduces the need to repeat the procedure. This phase 3 trial aims to determine if a one-week drug pause is a suitable recommendation prior to EGD for patients using GLP-1 RAs or tirzepatide. The study is randomized and double-blind, comparing patients who stop the drug for one week to those who do not. Participants are assigned to one of two groups one group stops GLP-1 RAs for one week before the EGD, and the other group continues their medication without interruption. The study assesses the cleanliness of the stomach lining during EGD using the PEACE scoring system, measured from enrollment to 30 days after treatment. Both groups receive standard care aside from the intervention to stop or continue GLP-1 RA use. During the trial, participants undergo routine outpatient visits, and their gastric preparation quality is evaluated during EGD. Researchers monitor the need for repeat EGD procedures and use the PEACE scoring system to assess stomach cleanliness. Participants must provide informed consent and meet eligibility criteria, including age and health status. The study completion is planned for June 2030, with primary outcome data collected up to 30 days post-treatment.

Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.